Hyabell, new hyaluronic acid (HA) dermal fillers with 0.3% lidocain, are designed for wrinkles and volume treatment. Hyabell products (Lips, Basic, Deep and Ultra) are crosslinked with 1,4-butanediol diglycidyl ether agent (BDDE), packed in 1x1ml packages and have different HA concentrations (12 to 24 mg/ml). Hyabell products passed all biocompatibility tests according to international standards and showed excellent longevity.
Due to the innovative monophasic particle technology (MPT) used for their production, Hyabell products are easier to inject and have significantly better elastic and viscous properties compared to other fillers. Injectability through a thin needle into soft tissue was measured for all four types of Hyabell gels, showing lower applied force and homogenous extrusion for Hyabell compared to other products. Crosslinking agent BDDE is biodegradable via hydrolysis and unreacted BDDE is less than 2 particle per million in the final product. The epoxide groups at the two ends of BDDE molecule form superior stable ether bonds with HA enabling a high crosslinking degree and lasting protection from enzyme degradation. Histological studies showed very good localization upon Hyabell injections and not any gel migration due to homogeneous particles and formulated final product. 12 months after subdermal application in rats, not any inflammatory processes were detected.